Abstract
In contrast to rheumatoid arthritis, in psoriatic arthritis (PsA), the efficacy of disease-modifying antirheumatic drugs (DMARDs) combination has not been documented. We conducted a retrospective study to evaluate the effectiveness of leflunomide (LEF) addition in 11 PsA patients with articular manifestations that failed to respond to methotrexate (MTX) monotherapy [disease activity score in 28 joints (DAS28) > 3.2)]. Eight of them, all with moderate disease activity (DAS28 < 5.1) at baseline, tolerated the combination. A statistically significant improvement of the mean DAS28, based on erythrocyte sedimentation rate (ESR), and its variables, and C-reactive protein (CRP) at 12–16 weeks after LEF addition was observed. Mean change of DAS28 in patients with polyarticular disease did not differ compared with those with oligoarticular. Based on the European League Against Rheumatism (EULAR) response criteria, none of our patients achieved a good response, seven had a moderate response, and one was a non-responder. The two patients with the lower DAS28 at baseline attained low disease activity (LDA, DAS28 ≤ 3.2), while none reached remission (DAS28 ≤ 2.6). Achievement of clinical remission or at least LDA has been recently proposed as the goal of treatment in PsA. Our results imply that LEF addition may serve as an alternative therapeutic modality for patients with moderately active PsA and, as lower as possible, residual disease activity after the initial therapy with MTX alone.
This is a preview of subscription content, log in via an institution to check access.
References
Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, For the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68:1387–1394
Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D et al (2012) European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71:4–12
Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH et al (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859–864
Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:987–994
Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733
Sakellariou GT, Sayegh FE, Kapatenos GA, Berberidis C (2012) Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. Clin Rheumatol 31:163–167
Kaul A, O’Reilly DT, Slack RK, Collins D, Walmsley J, Duke O, Kiely PD (2008) Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study. Rheumatology 47:1430–1431
Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 69:43–47
Bird P, Griffiths H (2010) Multi-centre, cross-sectional, observational study of the safety of methotrexate and leflunomide in combination in the treatment of patients with rheumatoid arthritis. The SMILE study—safety of methotrexate in combination with leflunomide. Arthritis Rheum 62(Suppl 10):319
Liang GC, Barr WG (2001) Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 7:366–370
Zhang GL, Huang F, Zhang JL, Li XF (2009) A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi 48:570–574
Glintborg B, Østergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide danish DANBIO registry. Arthritis Rheum 63:382–390
Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL, On behalf of the BSRBR (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the british society for rheumatology biologics register. Rheumatology 49:697–705
Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, For the Treatment of Psoriatic Arthritis Study Group et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950
Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L et al RESPOND investigators (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541–548
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakellariou, G.T., Sayegh, F.E., Anastasilakis, A.D. et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int 33, 2917–2920 (2013). https://doi.org/10.1007/s00296-012-2534-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2534-x